National Asset Management, Inc. Gilead Sciences, Inc. Transaction History

National Asset Management, Inc.

$3.82 Billion
Q2 2024

A detailed history of National Asset Management, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, National Asset Management, Inc. holds 35,674 shares of GILD stock, worth $3.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

35,674

Previous 28,519 25.09%

Holding current value

$3.3 Million

Previous $2.09 Million 17.14%

% of portfolio

0.06%

Previous 0.05%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 19, 2024	BUY	$63.15 - $72.88 $451,838 - $521,456	7,155 Added 25.09%	35,674 $2.45 Million
Q1 2024 May 16, 2024	BUY	$71.58 - $87.29 $43,234 - $52,723	604 Added 2.16%	28,519 $2.09 Million
Q4 2023 Mar 15, 2024	SELL	$73.27 - $83.09 $44,255 - $50,186	-604 Reduced 2.12%	27,915 $2.26 Million
Q3 2023 Dec 01, 2023	SELL	$73.94 - $80.67 $225,147 - $245,640	-3,045 Reduced 9.65%	28,519 $2.14 Million
Q2 2023 Jul 27, 2023	BUY	$76.01 - $86.7 $104,817 - $119,559	1,379 Added 4.57%	31,564 $2.43 Million
Q1 2023 May 17, 2023	BUY	$77.31 - $88.08 $27,754 - $31,620	359 Added 1.2%	30,185 $2.5 Million
Q4 2022 Feb 21, 2023	BUY	$62.32 - $89.47 $353,479 - $507,473	5,672 Added 23.48%	29,826 $2.56 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $355,275 - $405,815	5,967 Added 32.81%	24,154 $1.49 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $104,069 - $117,213	-1,803 Reduced 9.02%	18,187 $1.13 Million
Q1 2022 May 02, 2022	SELL	$57.92 - $72.58 $1.11 Million - $1.39 Million	-19,112 Reduced 48.88%	19,990 $1.19 Million
Q4 2021 Jan 28, 2022	SELL	$64.88 - $73.64 $91,415 - $103,758	-1,409 Reduced 3.48%	39,102 $2.84 Million
Q3 2021 Nov 16, 2021	BUY	$67.69 - $73.03 $152,167 - $164,171	2,248 Added 5.88%	40,511 $2.83 Million
Q2 2021 Aug 10, 2021	BUY	$63.47 - $69.35 $517,153 - $565,063	8,148 Added 27.06%	38,263 $2.64 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $709,500 - $809,539	11,825 Added 64.65%	30,115 $1.95 Million
Q4 2020 Feb 04, 2021	SELL	$56.65 - $64.55 $1.27 Million - $1.45 Million	-22,459 Reduced 55.12%	18,290 $1.07 Million
Q3 2020 Nov 09, 2020	BUY	$62.1 - $78.08 $40,675 - $51,142	655 Added 1.63%	40,749 $2.6 Million
Q2 2020 Jul 31, 2020	SELL	$72.34 - $84.0 $122,543 - $142,296	-1,694 Reduced 4.05%	40,094 $3.09 Million
Q1 2020 May 06, 2020	BUY	$62.63 - $80.22 $401,333 - $514,049	6,408 Added 18.11%	41,788 $3.13 Million
Q4 2019 Feb 10, 2020	BUY	$61.62 - $67.78 $1.12 Million - $1.24 Million	18,242 Added 106.44%	35,380 $2.3 Million
Q3 2019 Nov 12, 2019	BUY	$62.51 - $69.0 $240,663 - $265,650	3,850 Added 28.97%	17,138 $1.09 Million
Q2 2019 Aug 05, 2019	BUY	$61.87 - $69.38 $97,692 - $109,551	1,579 Added 13.49%	13,288 $898,000
Q1 2019 May 08, 2019	SELL	$62.53 - $70.05 $52,587 - $58,912	-841 Reduced 6.7%	11,709 $763,000
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $109,880 - $143,385	-1,815 Reduced 12.63%	12,550 $786,000
Q3 2018 Nov 08, 2018	SELL	$71.28 - $78.92 $74,844 - $82,866	-1,050 Reduced 6.81%	14,365 $1.11 Million
Q2 2018 Oct 05, 2018	SELL	$64.88 - $75.68 $106,792 - $124,569	-1,646 Reduced 9.65%	15,415 $1.09 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $89,447 - $109,046	-1,228 Reduced 6.71%	17,061 $1.29 Million
Q4 2017 Feb 15, 2018	SELL	$71.15 - $83.52 $424,267 - $498,029	-5,963 Reduced 24.59%	18,289 $1.31 Million
Q3 2017 Nov 13, 2017	SELL	$72.11 - $85.47 $145,517 - $172,478	-2,018 Reduced 7.68%	24,252 $1.97 Million
Q2 2017 Aug 15, 2017	BUY	N/A	26,270	26,270 $1.86 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on National Asset Management, Inc. with notifications on news.

Account

National Asset Management, Inc. Gilead Sciences, Inc. Transaction History